Upgrade alert! Top broker upgrades this small-cap ASX share and predicts 75% upside

Bell Potter has turned bullish on this stock after a key acquisition.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have a high tolerance for risk, then it could be worth checking out the small-cap ASX share in this article.

That's because the team at Bell Potter has just put a buy rating on its shares. Let's find out why it has turned bullish.

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.

Image source: Getty Images

Which small-cap ASX share?

The share that Bell Potter has turned bullish on is Doctor Care Anywhere Group PLC (ASX: DOC).

It is a UK-based telehealth company aiming to provide high quality, timely, and efficient primary and secondary care to patients, whilst reducing the overall cost of providing clinical services.

Bell Potter notes that it currently provides approximately 60,000 telephone/video consults per month. The vast majority of these are provided to the families of policy holders of a large private health insurance group operating in the UK.

The broker highlights that the small-cap ASX share has just announced an acquisition in the UK market, which it has described as a "pivotal moment" for the company. It said:

The acquisition of MedicSpot in the United Kingdom marks a pivotal moment in the company's evolution. It broadens the business from a single-client service provider driving +90% of revenues to a more diversified platform with the capability to serve the broader market for corporate healthcare which we believe has distinct advantages over competitors focussed on direct-to-consumer (D2C).

MedicSpot is a healthcare and wellness platform currently targeting the direct-to-consumer market in the UK. The major assets include the website (medicspot.co.uk) and the estimated 2,500 customers ordering GLP-1 weight loss products each month, generating the estimated £5.3m in annual revenue. DOC also inherited a headcount of just 11 persons who continue to operate the business.

The broker points out that this deal fixes a shortcoming in its offering which bodes well for future tenders. It explains:

Weight management programs are key to virtually every new tender in this market and this element has been a shortcoming for DOC to this point. The combination of the weight loss program with the existing offering for GP, musculoskeletal and mental health services is absolutely unique in the UK with no competitor offering this combination from a single platform.

Big potential returns

According to the note, Bell Potter has upgraded the small-cap ASX share to a buy rating (from hold) with an improved price target of 24 cents (from 20 cents).

Based on its current share price of 13.7 cents, this implies potential upside of 75% for investors over the next 12 months.

Commenting on the upgrade, Bell Potter said:

We believe the acquisition of MedicSpot for just £850K represents deep value. The business is close to breakeven at EBITDA while providing DOC with immediate access to the D2C wellness market which the company will rapidly adapt to the large corporate market. Following the acquisition we upgrade our recommendation from Hold to Buy. PT amended to $0.24 from $0.20.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Doctor Care Anywhere Group Plc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A group of six work colleagues gather around a computer in an office situation and discuss something on the screen as one man points and others look on with interest
Broker Notes

This mid-cap ASX tech share could be 30% higher in 12 months

Bell Potter has named this tech stock as a buy this week. Here's why it is bullish.

Read more »

Three smiling corporate people examine a model of a new building complex.
Broker Notes

Bell Potter says this ASX All Ords stock could rise 40% after record result

Let's see what the broker is saying about this stock.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Broker Notes

Morgans says these ASX shares could rise 12% to 20%

Let's see what the broker is recommending to clients this week.

Read more »

Broker looking at the share price.
Broker Notes

Buy, hold, sell: James Hardie, TechnologyOne, and Webjet shares

Let's see what analysts at Morgans are saying about these shares.

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Temple & Webster and James Hardie shares

A leading analyst expects James Hardie and Temple & Webster shares to continue to underperform. But why?

Read more »

Man sits smiling at a computer showing graphs.
Broker Notes

Why Morgans upgraded this ASX 200 share and downgraded another

The broker has updated its ratings on these shares.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Broker Notes

3 ASX shares Morgans rates as buys this week

Let's see what the broker is recommending to clients.

Read more »